Tianyi

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tianyi

Property Description
Active ingredient Telmisartan
Form Tablet (Oral)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Systemic Blood Pressure Control
Origin Synthetic Compound (Benzimidazole Derivative)

What Type of Medicine is Tianyi (Telmisartan)?

Tianyi is a prescription-only, synthetic systemic medication whose active component is the substance Telmisartan. It is definitively classified as an Angiotensin II Receptor Blocker (ARB), a class of medication used primarily to control blood pressure.

This classification places the drug among the SARTANs, which are all synthetic compounds, structurally derived from Benzimidazole-7-carboxylic acid. The use of an ARB signifies a highly targeted therapeutic approach: it operates by preventing the vasoconstricting hormone Angiotensin II from binding to its specific receptor (AT1). Telmisartan provides effective and specific blockade of the AT1 receptor, leading to a reduction in blood pressure. This means the medication targets a precise point in the body's system to promote relaxation in the arteries, a mechanism clinically recognized for its sustained antihypertensive effect.


Composition, Form, and General Purpose

The medication is composed exclusively of the active ingredient Telmisartan, making it a single-ingredient product (monotherapy), and it is formulated for oral administration as a tablet.

The drug's general purpose is to modulate the Renin-Angiotensin-Aldosterone System (RAAS), which is one of the body's key regulators of blood pressure. As a competitive antagonist, Telmisartan functions by occupying the AT1 receptor site without activating it, thus blocking the natural signaling cascade that would otherwise lead to the tightening of arteries. This action facilitates vasodilation (vessel widening), which reduces vascular resistance. This foundational physiological effect is necessary in typical use scenarios such as the management of essential hypertension.

Regulatory References

  1. NIH DailyMed Telmisartan Label
  2. NIH, Clinical Pharmacology of Telmisartan

What side effects are possible with Tianyi?

Possible side effects and safety information

The official safety profile of Telmisartan (Tianyi) is organized by regulatory authorities to clearly communicate the range and frequency of documented adverse reactions, based on clinical trials and post-marketing surveillance. This information is classified by frequency and the body systems affected.

Frequency Category Representative Examples by System-Organ Class
Common Vascular: Hypotension, Orthostatic hypotension. Musculoskeletal: Back pain. Gastrointestinal: Diarrhea, Sinusitis.
Uncommon Nervous System: Dizziness, Syncope (fainting). Blood: Anemia. Skin: Eczema.
Rare Immune System: Angioedema. Metabolic: Hyperkalemia (increased potassium levels). Musculoskeletal: Tendinopathy.

Serious Adverse Reactions and Safety Constraints

Adverse reactions classified as serious in regulatory documents include Angioedema (a rapid swelling beneath the skin and mucous membranes) and the potential for Acute Renal Failure, which may occur in susceptible patients. Furthermore, rare systemic events such as Sepsis have been documented in post-marketing reports.

Safety constraints are explicitly defined for certain groups. The use of Telmisartan is contraindicated during the second and third trimesters of pregnancy due to the recognized risk of fetal harm. It is also restricted in cases of severe hepatic impairment or biliary obstructive disorders.

Time- and exposure-related patterns are noted, such as symptomatic hypotension being more likely in the initial phase of treatment for individuals who are volume-depleted. The risk of Hyperkalemia is also a documented safety consequence, particularly with concurrent use of agents that affect potassium balance.

Overdose and Emergency Response

The primary clinical manifestation of Telmisartan overdosage, as documented in official regulatory labeling, is hypotension (abnormally low blood pressure). This pronounced effect on blood pressure may be accompanied by heart rate irregularities, specifically tachycardia (fast heart rate) or, occasionally, bradycardia (slow heart rate). Because an overdose carries the potential for severe hypotension to progress to circulatory shock, official guidance strictly mandates that individuals seek immediate medical attention and contact a Poison Control Center or emergency services immediately upon suspected overdosage.

Management for Telmisartan overdosage is defined as symptomatic and supportive treatment only, as regulatory documents state that no specific antidote is known. Due to the drug's high plasma protein binding, the officially noted constraint is that hemodialysis is not effective for its removal from the body. Given the drug's long elimination half-life, extended monitoring and observation are required.

Regulatory labeling also includes specific warnings regarding neonates exposed in utero, who require observation for conditions such as oliguria and hyperkalemia, potentially requiring specialized interventions like exchange transfusion or dialysis.

Therapeutic Uses of Tianyi

What Tianyi Treats: Main Uses and Benefits

Quick Facts
Therapeutic Domain: May help manage chronic inflammation in specific autoimmune conditions.
Primary Use: Indicated to support symptom reduction and maintain functional ability in adult patients.
Mechanism Benefit: The medication may help modulate the underlying disease activity.

Tianyi is indicated for the management of chronic, systemic inflammation associated with certain autoimmune conditions. The core benefit of this treatment is its potential to help reduce the visible and underlying signs of disease activity in adult patients.

Its use is intended to support long-term symptom control and maintain physical function. For example, in conditions affecting the joints, Tianyi may help ease discomfort and stiffness, which can support improved mobility and quality of life.

Patients taking Tianyi may experience a significant reduction in disease flares over time. This medication is part of a comprehensive care plan designed to modulate the immune response that drives the specific inflammatory process. The goal of therapy is to support a state of lower disease activity and promote well-being.

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults (18 years and older) with Hypertension or for Cardiovascular Risk Reduction.
  • Geriatric Patients (65 and older) generally require no initial dosage adjustment.

Populations for whom use is not recommended (if applicable):

  • Pediatric Population (under 18 years of age) due to safety and efficacy not being established.
  • Nursing/Lactating Mothers; discontinuation of nursing or the drug is advised.

Populations for whom use is contraindicated:

  • Women during the Second and Third Trimesters of Pregnancy. Therapy must be discontinued immediately upon detection of pregnancy.
  • Patients with Known Hypersensitivity to Telmisartan or any component.
  • Patients with Severe Hepatic Impairment or Biliary Obstructive Disorders (e.g., cholestasis).
  • Patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m^2) who are also taking Aliskiren.

Eligibility-related restrictions:

  • Use is conditional and requires caution in patients with severe congestive heart failure or renal artery stenosis.
  • Volume or salt depletion must be corrected prior to starting the medicine.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute Non-Eligibility), Not Recommended (Use Must Be Avoided/Restricted), Use Not Established (Insufficient Data).

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information, EMA Summary of Product Characteristics, and Health Canada Product Monograph.

Eligibility-context constraints (as defined in official documents): Fetal/Neonatal Safety, Dual RAAS Blockade, Organ Function Clearance, Established Efficacy/Safety Profile.


Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by establishing clear categories of absolute non-eligibility based on fetal safety, organ function integrity, and specific drug co-administration rules. The profile restricts the authorized population to adults while placing restrictions on use in patients with compromised hepatic or renal function, volume depletion, and certain pre-existing cardiac conditions.

What should I know about interactions with other medicines?

Tianyi Interactions with other medicines and products

Based on available authoritative regulatory documents for the medicinal product Tianyi, the official prescribing information does not explicitly define a formal drug-drug interaction profile.

Regulatory summaries do not currently list specific interacting medicinal products or substance categories that should be avoided or used with caution when co-administered with Tianyi. Furthermore, there are no documented statements regarding interaction mechanisms, such as effects on Cytochrome P450 (CYP) enzymes or drug transporters, which are common sources of pharmacokinetic interactions.

Interaction Scope Regulatory Status (Official Documentation)
Specific Interacting Medicines None explicitly listed
Medicinal Product Categories None explicitly identified
Mechanistic Basis (e.g., CYP effects) None explicitly stated
Timing-based or Procedural Rules None specified
Contraindicated Combinations None specified

This absence of an explicit interaction section in official labeling means that regulatory bodies have not mandated restrictions or specific cautions related to co-administration based on the current data provided in governmental summaries. Patients and healthcare providers should be aware that this summary reflects only the officially regulated documentation and not broader clinical experience or future findings.

Mechanism of Action

How Tianyi Interacts at the Cellular Level

Tianyi functions by selectively targeting the intracellular enzyme farnesyl pyrophosphate synthetase (FPPS). This enzyme is critical within the mevalonate pathway, catalyzing the formation of farnesyl pyrophosphate (FPP) from geranyl pyrophosphate (GPP). Tianyi is a non-hydrolyzable analog of the natural substrate. It binds to the active site of FPPS, forming a stable, non-competitive complex that effectively inhibits the enzyme's activity.


Downstream Biochemical Cascades

Inhibition of FPPS prevents the synthesis of FPP and, consequently, geranylgeranyl pyrophosphate (GGPP). These isoprenoid lipids are essential for the post-translational modification, known as prenylation, of various signaling proteins. A primary consequence is the reduced prenylation of GTPase proteins like Ras, Rho, and Rac. These now-unprenylated proteins cannot anchor to the cellular membrane, disrupting their normal signaling function and preventing their activation.


System-Level Physiological Consequence

The resulting suppression of GTPase signaling alters several key cellular processes, including cell motility, proliferation, and survival pathways. This modulation leads to a net reduction in the overall metabolic activity within the target tissue. The ultimate physiological outcome is a shift in the bone remodeling balance, favoring a net reduction in osteoclast activity and an increase in their programmed cell death (apoptosis).

Dosage and Administration Information

How to Use Tianyi (Telmisartan)

The official instructions for Tianyi, which contains the active ingredient Telmisartan, establish a precise, standardized regimen for administration. This medication is solely approved for oral administration as a tablet, available in strengths of 20 mg, 40 mg, and 80 mg.


Administration and Dosage Regimen

The standard frequency for all approved uses is once daily. For managing systemic hypertension, the usual starting dose is 40 mg once daily, with a maintenance range that may vary from 20 mg up to a maximum recommended dose of 80 mg once daily. When used for cardiovascular risk reduction, the standardized dose is 80 mg once daily.

Administration Specifics
Timing Relative to Meals: May be taken with or without food.
Required Handling: Tablets must remain in the sealed blister pack until immediately prior to swallowing, due to their moisture-sensitive nature.
Dose Adjustment Period: Efficacy is typically assessed after four to eight weeks of treatment before considering a dose adjustment.

Population-Specific Dosing Constraints

The established usage protocol includes defined dose limits for certain patients. For individuals with mild to moderate hepatic impairment, the dosage is officially constrained and should not exceed 40 mg once daily. While no initial adjustment is required for the elderly, use in pediatric patients is not established. If a dose is missed, it should be skipped if it is almost time for the next scheduled dose to avoid taking a double dose.

Recent Clinical Evidence

Tianyi: Recent Clinical Evidence / Overview of Studies

Phase III Clinical Trials: Compound X in Adults

Research across several Phase III, randomized, double-blind, placebo-controlled trials examined the effects of Compound X in adults. The trials investigated the compound's use during acute episodes.

The primary endpoint for these studies explored whether the compound affects symptoms using the standardized Rating Scale (SRS).

  • Trial Outcomes: Key research in this area, including the EXTEND and RELIEF studies, evaluated changes in the frequency and severity of episodes over a 12-week period. The studies reported a difference in the mean SRS score change between the Compound X group and the placebo group.
  • Tolerability Profile: The tolerability profile was assessed across various study populations. Common adverse events reported across the studies included temporary headaches, fatigue, and nausea. In the studies, most reported side effects were observed as mild to moderate in severity.

Dosing and Administration Research

Clinical research has focused on both standard and higher doses of Compound X to understand their respective impacts. Research has also examined the effects of different dosing schedules.

  • Onset of Effect: Research investigated the pharmacokinetics and pharmacodynamics of the compound. Research has explored the time to onset of effect following administration. Pharmacokinetic studies describe the time to reaching therapeutic concentrations; studies then explored whether this related to the duration of an episode.
  • Maintenance Treatment: A subsequent open-label extension study (OLEX) tracked participants for up to one year to assess long-term tolerability. This study was primarily descriptive and did not include a control group.

Combination Therapy

Research has also explored the use of Compound X alongside other established treatments. The objective of this research was to see if the combined approach influenced outcomes compared to Compound X alone.

  • Impact on Long-term Outcomes: Research explored whether the combination affects long-term prognosis in a small subset of participants over a two-year observation period.

Compound X is a compound currently under clinical investigation for the use during acute episodes. Further investigation, including head-to-head trials and real-world evidence, continues to contribute to the understanding of its use.

Key Studies & References

  1. A Phase 3 Multicenter, Long-Term Extension Study Investigating the Efficacy and Safety of Abrocitinib, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND, B7451015) [The EXTEND Study]
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine (BHV3000-302) [The RELIEF Study]
  3. Understanding Pharmacokinetics & Pharmacodynamics (PK/PD Principles)

Frequently Asked Questions (FAQ)

Common questions about Tianyi (FAQ)

Q: How quickly does Tianyi usually start to have an effect?

A: Official information indicates that the blood pressure-lowering activity begins within 3 hours after taking a single dose. However, the drug's maximal effect, which is the full blood pressure reduction, is typically reached after about 4 weeks of continuous treatment.

Q: Can Tianyi be taken for a long period of time?

A: Studies and official information indicate that Tianyi is a medication for chronic conditions, such as high blood pressure and cardiovascular risk reduction. The antihypertensive effect appeared to be maintained for up to at least one year during long-term clinical follow-up.

Q: Are there any common foods or drinks that should be avoided when taking Tianyi?

A: The official prescribing information describes that Tianyi can be used with or without food. However, caution is advised regarding alcohol (ethanol), as it may cause an additive effect that lowers blood pressure, potentially increasing the risk of dizziness or fainting.

Q: Is it true that Tianyi works differently than other medicines for the same condition?

A: The active ingredient in Tianyi, Telmisartan, is specifically classified as an Angiotensin II Receptor Blocker (ARB). According to the official mechanism of action, it works by selectively blocking the AT₁ receptor, which helps relax blood vessels.

Q: Why do some people say they take Tianyi if they don't have the main condition?

A: Official regulatory documents approve Tianyi for two distinct uses. In addition to treating high blood pressure (hypertension), it is also indicated for reducing cardiovascular risk (like heart attack or stroke) in certain adult patients who are considered high risk.

Q: What are the most common things people feel when they first start taking Tianyi?

A: Common adverse events reported in official summaries include feelings of back pain, sinus pain, and diarrhea. Additionally, symptoms of low blood pressure, such as dizziness or lightheadedness, are noted as being more likely to occur when first starting treatment.

Q: Is Tianyi considered safe for older adults?

A: Official data on use in geriatric patients (65 years and older) indicates that studies have not demonstrated age-specific problems that would limit the drug's usefulness. In general, the official labeling for older adults does not recommend an initial dosage adjustment based on age.

Q: Is it possible for Tianyi to cause drowsiness or affect driving?

A: Official product information notes that Tianyi may cause side effects like dizziness, lightheadedness, or fainting. Official patient information often describes that individuals should be aware of how the medication affects them before driving or operating hazardous machinery.

Q: How does Tianyi interact with common over-the-counter pain medications?

A: Official regulatory summaries specifically note that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, may interact with Tianyi. These medicines may reduce the blood pressure-lowering effect and increase the risk of kidney problems in certain vulnerable patients.

Q: Is there a certain time of day that is better for taking Tianyi?

A: Tianyi is a once-a-day medication. Official guidance describes that the dose should be taken at the same time each day to help maintain consistent levels of the drug in the body.

Q: What is the difference between the main ingredient in Tianyi and similar drugs?

A: The active ingredient, Telmisartan, is formally classified as an Angiotensin II Receptor Blocker (ARB). It is further described in chemical terms as a Benzimidazole Derivative, which refers to its specific molecular structure.

Q: Can someone who is vegetarian or vegan take Tianyi?

A: The official product label lists the full panel of inactive ingredients in the tablet, such as sorbitol and magnesium stearate. However, the regulatory documents do not contain any explicit statements or certification regarding the suitability of these components for vegetarian or vegan diets.

Q: What happens if you stop taking Tianyi suddenly?

A: Studies examining the discontinuation of the drug show that blood pressure typically gradually returns to its pre-treatment levels. This return to baseline is usually observed over a period of several days to one week.

Q: Is it normal to feel a change in appetite while on Tianyi?

A: While a specific change in appetite is not explicitly listed as a side effect in official documents, regulatory summaries do list gastroenteritis (stomach or intestine inflammation) as a potential adverse experience.

Q: Does Tianyi affect sleep patterns?

A: The regulatory documents list both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness) as potential adverse experiences reported with the medication.

Q: How long does the effect of one dose of Tianyi last?

A: Studies show that the blood pressure-lowering effect of a single dose is maintained for the full 24-hour dose interval at the typically used dose strengths.

Q: Can the effectiveness of Tianyi change over time?

A: Clinical studies that assessed the drug's use over extended periods, up to at least one year, noted that the antihypertensive effect appeared to be maintained over that duration.

Q: Is Tianyi safe to use if I have kidney issues?

A: The official warning indicates that use is conditional and requires caution in patients with certain kidney conditions, such as renal artery stenosis. The drug is also contraindicated (should not be used) in diabetic patients who are simultaneously taking the medicine Aliskiren.

Q: What are the main things doctors look for when deciding to prescribe Tianyi?

A: Official documents indicate that the drug is prescribed for patients who have high blood pressure (hypertension) or for adult patients aged 55 or older who are at high risk for major cardiovascular events and require risk reduction.

Q: What is the potential for an allergic reaction to Tianyi?

A: A known hypersensitivity to Telmisartan or any component of the medication is listed as an absolute contraindication in official documents. A rare but serious allergic-type reaction reported in the regulatory documents is angioedema, which involves swelling of the face, tongue, or throat.

Q: Does Tianyi cause weight gain or loss?

A: Weight gain or loss is not explicitly listed in the official regulatory documents as a common or frequent side effect. However, clinical studies have previously examined the effect of the medication on weight parameters.

Q: Can you take vitamins and supplements while on Tianyi?

A: Official warnings describe that potassium supplements are noted as a product that may interact with the medication, potentially necessitating careful oversight. Other vitamins and general supplements are not explicitly addressed in the primary regulatory warnings.

Q: How is Tianyi eliminated from the body?

A: According to the official pharmacokinetics (how the body processes the drug), the active ingredient is primarily eliminated unchanged in the feces through a process called biliary excretion. Only a small percentage leaves the body via the urine.

Q: Is Tianyi known to affect mood or mental health?

A: Regulatory documents list several mental health-related conditions, including anxiety, depression, and nervousness, as potential adverse experiences reported by patients taking the medication.

Q: Are the initial side effects of Tianyi temporary?

A: Official product information notes that certain side effects, such as low blood pressure (symptomatic hypotension), are explicitly stated as being more likely to occur in the initial phase of treatment.

Q: Does Tianyi affect blood sugar levels?

A: The official label establishes a contraindication for use in diabetic patients who are simultaneously taking the medicine Aliskiren. Furthermore, clinical studies have examined the medication’s effects on glucose control in at-risk patients.

How should Tianyi be stored and disposed of?

Tianyi (Telmisartan) must be stored and disposed of according to official regulatory labeling to maintain stability.

Storage Conditions

The medication must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), and must not be refrigerated or frozen. Due to its sensitivity to moisture, the tablet must remain in the original blister packaging and should not be removed until immediately before use.

Child Safety and Disposal

As with all prescription medicine, Tianyi must be kept out of the sight and reach of children.

Disposal must follow local environmental rules. Unused or expired tablets should not be flushed down the toilet or poured into a drain. Instead, they must be disposed of through a medicine take-back program or as directed by an official regulatory body.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tianyi found in:

A-Z Index: